"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 5 | 6 |
| 2006 | 2 | 3 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 3 | 5 |
| 2009 | 5 | 2 | 7 |
| 2010 | 3 | 2 | 5 |
| 2011 | 3 | 0 | 3 |
| 2012 | 8 | 3 | 11 |
| 2013 | 2 | 4 | 6 |
| 2014 | 6 | 3 | 9 |
| 2015 | 11 | 6 | 17 |
| 2016 | 8 | 5 | 13 |
| 2017 | 4 | 4 | 8 |
| 2018 | 5 | 4 | 9 |
| 2019 | 3 | 6 | 9 |
| 2020 | 6 | 5 | 11 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 4 | 4 |
| 2024 | 4 | 0 | 4 |
| 2025 | 1 | 4 | 5 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 2026 Feb; 40(2):304-313.
-
Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome. Orphanet J Rare Dis. 2025 Jul 25; 20(1):375.
-
Tumor pH-triggered PEG detachable nanoparticles for TLR7/8 agonist delivery to improve cancer immunotherapy. Biomater Sci. 2025 May 13; 13(10):2794-2805.
-
Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to Clostridioides difficile infection. Cell Rep. 2025 Apr 22; 44(4):115438.
-
An albumin-prodrug injectable formulation for synergistic cancer immunotherapy. J Colloid Interface Sci. 2025 May 15; 686:1019-1032.
-
A size-switchable nanocluster remodels the immunosuppressive microenvironment of tumor and tumor-draining lymph nodes for improved cancer immunotherapy. Biomaterials. 2025 Apr; 315:122910.
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 11 07; 391(18):1709-1720.
-
Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy. ACS Appl Mater Interfaces. 2024 May 22; 16(20):25665-25675.
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15; 130(10):1784-1796.